← Back to Clinical Trials
Recruiting NCT05190211

NCT05190211 Telerehabilitation in Patients With Idiopathic Pulmonary Fibrosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05190211
Status Recruiting
Phase
Sponsor Istanbul Medipol University Hospital
Condition IPF
Study Type INTERVENTIONAL
Enrollment 44 participants
Start Date 2021-11-26
Primary Completion 2026-08-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Telerehabilitation exercise programVideobased exercise program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 44 participants in total. It began in 2021-11-26 with a primary completion date of 2026-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

It is to determine the effectiveness of different telerehabilitation exercise programs received to 2 groups randomly formed in idiopathic pulmonary fibrosis (IPF) patients. The cases meeting the inclusion criteria will be randomized and divided into two groups, the groups will be named as Telerehabilitation Exercise Group (TGr) and Video Group (VGr).

Eligibility Criteria

Inclusion Criteria: * Being between the ages of 18-75 * Having a diagnosis of IPF disease diagnosed according to the following clinical diagnostic criteria according to the American Thoracic and European Respiratory Societies (ATS-ERS) * Presence of dyspnea on exertion * Stable clinical state at the time of admission without infection or exacerbation in the previous 4 weeks Exclusion Criteria: * Patients with severe comorbid diseases, unstable coronary artery disease, collagen vascular diseases and needing high flow oxygen therapy (˃ 3-4 L \\min). * A history of effort-related syncope or any comorbidity (such as severe orthopedic or neurological deficits or unstable heart disease) that precludes exercise training. * Participation in a pulmonary rehabilitation program within the past 12 months.

Frequently Asked Questions

Who can join the NCT05190211 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying IPF. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05190211 currently recruiting?

Yes, NCT05190211 is actively recruiting participants. Visit ClinicalTrials.gov or contact Istanbul Medipol University Hospital to inquire about joining.

Where is the NCT05190211 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT05190211 clinical trial?

NCT05190211 is sponsored by Istanbul Medipol University Hospital. The trial plans to enroll 44 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology